Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 32 n° 25

Posts Tagged ‘Pfizer’

Per la prima volta Pfizer in Italia presenta il suo Bilancio di Sostenibilità

Posted by fidest press agency su giovedì, 5 dicembre 2019

E’ un documento che riassume obiettivi, attività, impatti e risultati dell’azienda sul territorio nazionale. All’interno del calendario di eventi della rassegna Italia Direzione Nord (Fondazione Stelline 2 e 3 dicembre) ha avuto luogo la conferenza stampa di presentazione del documento illustrato da Marco Maffei, Partner KPMG; Guido Di Donato, Finance Director and Regional Finance Lead Vaccines for International Developed Markets Pfizer Italia; Emanuele Monti, Presidente Commissione Salute Regione Lombardia. Gli elementi del bilancio di Sostenibilità sono stati raccolti e certificati con il supporto di società esterne specializzate, basandosi sugli indicatori di sostenibilità stabiliti dall’ONU.Il documento è stato redatto sulla base degli obiettivi di Pfizer in Italia, in relazione alla performance di sostenibilità e alla rendicontazione dei risultati conseguiti. I dati sono stati calcolati in modo puntuale sulla base delle risultanze della contabilità generale e degli altri sistemi informativi utilizzati.Il Bilancio di Sostenibilità 2017 è oggetto di revisione limitata da parte di KPMG S.p.A.
Lo strumento di reporting prende in considerazione gli impatti non solo economici ma anche sociali e ambientali dell’attività quotidiana di Pfizer e contemporaneamente le aspettative dei propri stakeholder, oltre a testimoniare il percorso di trasparenza e miglioramento continuo di Pfizer Italia che intende integrare i driver di sostenibilità nel proprio modo di fare business. «Passare dal percepito numerico alla sostenibilità sui territori è un obiettivo che ci siamo posti e che ci ha guidati nella decisione di stilare il documento – ha dichiarato Di Donato-. L’impatto economico sicuramente crea un indotto, l’impatto ambientale è sempre stato al centro dell’attenzione di Pfizer e quello sociale ci dà la reale misura della ricaduta dell’azienda sul territorio».
La sede milanese di Pfizer conta oltre 200 dipendenti, inclusi i dipendenti della forza vendite. Le funzioni che operano nella sede sono: farmacovigilanza, Clinical Development Oncology, Worldwide Regulatory Strategy (Oncology), Global Chemistry Manufacturing and Control.Nonostante la Lombardia non sia un sito produttivo risulta essere, secondo il documento, la regione più virtuosa sotto il profilo sanitario. «Parlare di un bilancio di sostenibilità significa essere precursori del futuro- ha dichiarato il Presidente della Commissione Salute della regione Lombardia Monti-. La Lombardia per questo accoglie di buon grado le aziende che operano sul proprio territorio investendo nel miglioramento della salute dei cittadini e creare una valorizzazione che da un lato dà beneficio all’impresa, dall’altro allo Stato stesso».

Posted in Economia/Economy/finance/business/technology | Contrassegnato da tag: , , | Leave a Comment »

Pfizer and Allergan merger makes sense in an industry forcing a race for scale

Posted by fidest press agency su martedì, 24 novembre 2015

Expert comment on the newly announced merger between Pfizer and Allergan, John Colley, Professor of Practice at Warwick Business School and an expert on large-scale mergers, has made the following comments:”Botox producer Allergan has been acquired for $160Bn by Pfizer to make it the world’s largest pharmaceutical business. This deal follows a pattern in which the pharmaceutical industry has seen acquisitions totalling over $600Bn this year as the industry consolidates. “Industry valuations increase as industry players become concerned at being left behind in the race for scale. In the instance of Pfizer it is also pursuing greater growth as its own established products are losing patent protection at a greater rate than it can produce innovative products. “Allergan’s drug portfolio has greater potential for growth. In addition the lure of tax advantages from a Dublin Head Office has been a significant factor in driving this deal. The threat of succumbing to US tax rates has meant that Pfizer has been desperate for a deal outside the U.S. The failure of the AstraZeneca bid in a consolidating industry has driven the substantial price paid for Allergan.”In a year in which low interest rates, relatively benign markets, reasonable growth prospects and institutions awash with cash there is likely to be a record number of deals exceeding the previous record of $4.6 Trillion in 2007. “Most deals this year have been consolidations within an industry which have a clear strategic logic and as a consequence slightly lower risk. AB InBev and SAB Miller, Dell and EMC, Holcim and Lafarge are designed to exploit greater market power through size and generate substantial cost savings through scale and scope economies. Head Office and Regional management are generally key targets.”Both institutions and businesses draw confidence from ‘strength in numbers’ which encourages more deals. Despite the enormous risks associated with acquisitions in which over half destroy value and 60 to 80% materially fail to deliver expected benefits the rush goes on. “Research shows that the biggest reason for acquisitions failing to deliver benefits is simply paying too much! One wonders how many of the 2015 deals will ultimately fail to deliver value. My money is on more than half.”
Warwick Business School, located in central England, is the largest department of the University of Warwick and the UK’s fastest rising business school according the Financial Times. WBS is triple accredited by the leading global business education associations and was the first in the UK to attain this accreditation. Offering the full portfolio of business education courses, from undergraduate through to MBAs, and with a strong Doctoral Programme, WBS is the complete business school. Students at WBS currently number around 6,500, and come from 125 countries. Just under half of faculty are non-UK, or have worked abroad. WBS Dean, Professor Mark P Taylor, is among the most highly-cited scholars in the world and was previously Managing Director at BlackRock, the world’s largest asset manager.

Posted in Estero/world news, Spazio aperto/open space | Contrassegnato da tag: , | Leave a Comment »

Proposed AstraZeneca Megamerger a “Complementary Fit” with Pfizer Thanks to Potential Pipeline Gains, says GlobalData

Posted by fidest press agency su giovedì, 15 maggio 2014

londonLONDON, UK (GlobalData) As Pfizer’s potential takeover of AstraZeneca looms closer, the success in its bid for consolidation with AstraZeneca would result in promising pipeline gains and more than solidify its position as the world’s largest pharmaceutical company, at a time when Swiss giants Novartis and F. Hoffman-La-Roche are closing in on its historical leadership, says research and consulting firm GlobalData.Joshua Owide, GlobalData’s Director of Healthcare Industry Dynamics, states that this deal would be unlike any other in Pfizer’s corporate evolution to date, as the majority of value involved in the merger attempt would come from Pfizer’s ability to nurture ongoing research and development (R&D) activities at AstraZeneca.GlobalData also believes that a Pfizer/AstraZeneca megamerger could create an R&D juggernaut, with aggregate expenditure of over $11 billion, surpassing current R&D spending leaders Novartis and Roche. Additionally, this consolidation would create a pipeline with overall projected sales of $10.8 billion in 2019.Owide says: “The proposed purchase of AstraZeneca appears to be a very complementary fit with Pfizer, especially given the latter’s plans to spin off some of the mature components of its prescription pharmaceutical business.“AstraZeneca’s expiring drugs would meld into Pfizer’s Established Products division, and the former’s promising pipeline would bolster the other two Pfizer business units, which focus on new medications and consumer health, making them prime candidates for divestment.”  Pfizer and AstraZeneca both have complementary areas in R&D, and a merger would give Pfizer a much larger oncology pipeline in particular, thanks to the fold-in of AstraZeneca’s late-stage, anti-cancer agents. These include moxetumomab, olaparib and tremelimumab, which is a candidate developed by Pfizer and licensed to MedImmune.Indeed, with Roche having launched its latest generation of oncology antibody therapies in 2013, AstraZeneca now boasts the most promising oncology pipeline in the industry, with projected 2019 revenues of $4.7 billion, ahead of Merck & Co. and Bristol-Myers Squibb. Furthermore, AstraZeneca is currently investigating compounds in 60 oncology indications across Phase I and Phase II trials, representing a significant strategic opportunity for Pfizer.Owide states that the implications of this are significant. The branded oncology market is forecast to grow by annual sales of $76.7 billion between 2013 and 2019, making it the largest disease market by a sizable margin and also the fastest-growing one, with a CAGR of 10.5%.He continues: “The potential gain that Pfizer could extract from AstraZeneca’s pipeline, in relation to other components of the combined business, shows that any value from its deal with AstraZeneca would be heavily tied to its ability to nurture the UK giant’s emerging pipeline.“Of course, such a deal would carry a high level of risk, and Pfizer will look to argue this point as it attempts to convince AstraZeneca’s management and shareholders to relinquish their control for a fair price,” Owide concludes.

 

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »